Cross-gender hormone therapy in adolescents

Pediatric Annals

Volumn 43, Issue 6, 2014, Pages

  Steever, John ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; ESTRADIOL; ESTRADIOL VALERATE; FINASTERIDE; GONADORELIN AGONIST; SPIRONOLACTONE; TESTOSTERONE CIPIONATE;

ARTICLE; BONE DENSITY; FOLLOW UP; HEALTH IMPACT ASSESSMENT; HORMONAL THERAPY; HUMAN; IMMUNIZATION; LABORATORY TEST; MEDICAL CARE; PHYSICAL EXAMINATION; QUALITY OF LIFE; SEX DIFFERENCE; TRANSGENDERISM; ADOLESCENT; GENDER IDENTITY; HEALTH CARE QUALITY; HORMONE SUBSTITUTION; SEXUAL BEHAVIOR; STANDARDS; TRANSGENDER; TRANSSEXUALISM;

ADOLESCENT; GENDER IDENTITY; HORMONE REPLACEMENT THERAPY; HUMANS; SEXUAL BEHAVIOR; STANDARD OF CARE; TRANSGENDERED PERSONS; TRANSSEXUALISM;

EID: 84902778532     PISSN: 00904481     EISSN: 19382359     Source Type: Journal    
DOI: 10.3928/00904481-20140522-09     Document Type: Article

References (23)

1. Olson J. Management of the transgender adolescent. Arch Pediatr Adolesc Med. 2011;165(2):171-176.
2. Byne W, Bradley SJ, Coleman E, et al. Report of the American Psychiatric Association Task Force on Treatment of Gender Identity Disorder. Arch Sex Behav. 2012;41(4):759-796.
3. Hembree WC. Guidelines for pubertal suspension and gender reassignment for transgender adolescents. Child Adolesc Psychiatr Clin N Am. 2011;20(4):725-732.
4. Coleman E, Brockting W, Butzer M. Standards of care for the health of transsexual, transgender, and gender-nonconforming people. Int J Transgenderism. 2011;13:165-232.
5. Cohen-Kettenis PT. Treatment of adolescents with gender dysphoria in the Netherlands. Child Adolesc Psychiatr Clin N Am. 2011;20(4):689-700.
6. Drummond KD. A follow-up study of girls with gender identity disorder. Dev Psychol. 2008;44(1):34-45.
7. Hembree WC. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009;94(9):3132-3154.
8. Gooren L. Hormone treatment of the adult transsexual patient. Horm Res. 2005;64(suppl 2):31-36.
9. Moore E. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab. 2003;88(8):3467-3473.
10. Mueller A. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2008;159(3):197-202.
11. Garofalo R. Overlooked, misunderstood and at-risk: exploring the lives and HIV risk of ethnic minority male-to-female transgender youth. J Adolesc Health. 2006;38(3):230-236.
12. Cohen E. HEADSS, a psychosocial risk assessment instrument: implications for designing effective intervention programs for runaway youth. J Adolesc Health. 1991;12(7):539-544.
13. Gorin-Lazard A. Is hormonal therapy associated with better quality of life in transsexuals? A cross-sectional study. J Sex Med. 2012;9(2):531-541.
14. Plosker GL, Brogden RN. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Drugs. 1994;48(6):930-967.
15. Wierckx K. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med. 2012;9(10):2641-2651.
16. Biro FM, Huang B, Crawford PB, et al. Pubertal correlates in black and white girls. J Pediatr. 2006;148(2):234-240.
17. Gooren LJ. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab. 2008;93(1):19-25.
18. Seal LJ. Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens. J Clin Endocrinol Metab. 2012;97(12):4422-4428.
19. Toorians AWFT. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab. 2003;88(12):5723-5729.
20. Meyer M. Physical and hormonal evaluation of transsexual patients: a longitudinal study. Arch Sex Behav. 1986;15(2):121-138.
21. Zitzmann M. Endogenous progesterone and the exogenous progestin norethisterone enanthate are associated with a proinflammatory profile in healthy men. J Clin Endocrinol Metab. 2005;90(12):6603-6608.
22. Writing Group for the Women's Health Initiative I. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
23. Carr BR. Estrogen and progestin components of oral contraceptives: relationship to vascular disease. Contraception (Stoneham). 1997;55(5):267-272.